Accelr8's Q2 Revenues Drop Sharply As Novartis Deal Ends | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelr8 reported last week that its fiscal second-quarter revenues plummeted to $8,328 from $313,568 a year ago as a result of the expiration of an agreement with Novartis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.